Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 4Lymphoma, Non-Hodgkin 2Waldenstrom Macroglobulinemia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Graft vs Host Disease 1Bronchiolitis Obliterans Syndrome 1

Interventions

tofacitinib 7ofatumumab 4ibrutinib 4Rituximab 2KW-2478 2Dasatinib 2Alemtuzumab 2ziconotide 1sodium luminolate 1ruxolitinib 1oblimersen 1obinutuzumab 1mocetinostat 1milatuzumab 1ixekizumab 1fludarabine 1fenebrutinib 1baricitinib 1abexinostat 1Saline Solution 1Lenalidomide 1Hsp90 inhibitor KU757 1Etanercept 1Cyclophosphamide 1Bortezomib 1B3(Fv)-PE38KDEL recombinant immunotoxin 14-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bronchiolitis Obliterans Syndrome × milatuzumab × Lymphoid × Clear all
NCT01663766 2021-08-19

Phase I Study of Milatuzumab for Graft Versus Host Disease

Gilead Sciences

Phase 1 Terminated
12 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡